Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Two large clinical trials determined that each PEG-IFN alfa compound, when given in combination with ribavirin, results in overall sustained virological response (SVR) rates of approximately 50%; SVR rates in patients infected with hepatitis C virus (HCV) genotype 1 are typically lower (42-46%). 18363672

2008

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Together, we conclude that serum apoB-100 concentrations could predict virological response to Peg-IFN plus RBV combination therapy in patients infected with HCV G1b, especially in those with the rs8099917 hetero/minor genotype. 23918536

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. 26581744

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Genome-wide transcriptional profiling was performed on peripheral blood mononuclear cells (PBMCs) from 21 patients with chronic hepatitis C virus (HCV) either awaiting IFN-α therapy (n=10) or at 12 weeks of IFN-α treatment (n=11). 22152193

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Interferon (IFN) lambda (IFN-λ or type III IFN) gene polymorphisms were discovered in the year 2009 to have a strong association with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection in human hosts. 27278127

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE HCV amino acid (aa) substitutions in non-structural protein 5a, including those in the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region and the core regions, as well as the genetic variation (rs8099917) near the interleukin 28B (IL28B) gene (genotype TT) were analyzed. 22441534

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE As chimeric mice have the characteristic of immunodeficiency, the response to peg-IFN-α associated with the variation in IL28B alleles in chronic HCV patients would be composed of the intact immune system. 23135762

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE IL28B rs8099917/rs12979860 is useful in the treatment of MC-positive HCV patients with PEG-IFN and ribavirin; the TT/CC genotype is associated with SVR, the TG/TC with non-SVR; TT/CC is also predictive of MC in HCV patients. 26060059

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE HBV integration was associated with favorable viral responses and a higher SVR rate to combination therapy with PEG-IFN and ribavirin in patients infected with HCV genotype 1b. 23842217

2014

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Long-term culture with IFN-α2b in Huh7.5 cells resulted in viral spread with acquisition of putative escape mutations in HCV structural and nonstructural proteins. 24049176

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Productive infections have been achieved recently with genotype 2a virus, but cirrhosis and liver cancer are typically associated with genotype 1 HCV, which is more prevalent and relatively resistant to IFN therapy. 16461899

2006

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Forty-five naïve patients chronically infected with hepatitis C virus (HCV)-1b started Peg-IFN-alpha2b (1.5 microg/kg/week) in combination with weight-based RBV doses (800-1200 mg/day). 18307592

2008

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE This study aimed to determine the association of rs2430561 and rs4073 polymorphisms in the Interferon gamma (IFN-ɤ) and Interleukin 8 (IL-8) genes, respectively, with hepatitis C virus-related oral lichen planus and disease severity. 30290294

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Genotypic analysis of patients suffering recurrent orofacial HSV-1 outbreaks, previously shown to be deficient in IFN-λ secretion, found a significant correlation with a single nucleotide polymorphism in the IFN-λ3 (IL28b) promoter strongly linked to Hepatitis C disease and treatment outcome. 23950709

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE We prospectively studied baseline and during-treatment factors associated with a sustained virological response (SVR) in HCV genotype 3-infected patients who received pegylated interferon alfa-2a (PEG-IFN α2a) 180 μg/week plus ribavirin 800 mg daily for 24 weeks and who were followed for 24 weeks after the completion of treatment. 22658873

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Here, we discuss IFN-λ genetic polymorphisms and their role in HCV and other infectious diseases as well as their potential impact on clinical diagnostics, patient stratification and therapy. 25634147

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE One hundred eight HCV chronically infected patients initiating treatment with pegylated IFN plus ribavirin for 48 wk were tested for baseline substitutions at codons 70 and 91 of the viral core protein (BigDye Terminator vers.3.1, Applied Biosystems,) and for genetic polymorphisms in host <i>IL28B</i> gene rs12979860 (Custom TaqMan 5' allelic discrimination assay; Applied Biosystems). 27729747

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE This study aimed to evaluate whether genetic polymorphisms of the inducible nitric oxide synthase (iNOS) gene NOS2A could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNα-RBV). 23918539

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Amongst Caucasian, Hispanic and African Americans with genotype 1 hepatitis C virus (HCV), there is a wide variation in response to treatment with peginterferon alfa-2a (PEG-IFN alfa-2a) and ribavirin. 22469033

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Fourteen patients infected with HCV genotype 1b (HCV-1b) who were treated with pegylated IFN-α-2a and ribavirin for 24 weeks, were studied. 23064792

2012

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE We compared IFNL4-ΔG/TT and rs4803217 for association with response to pegylated-IFN-α/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. 26186989

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Larger prospective studies of patients with HCV genotype 6 are needed to confirm the optimal treatment duration with PEG IFN + RBV. 18477343

2008

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Variants of rs2111485 and rs1990760 at <i>IFIH1</i> may be associated with spontaneous HCV clearance in Chinese Han population, but have no effect on HCV clearance induced by IFN-<i>α</i>. 31539314

2019

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE One fifth to one fourth of hepatitis C virus genotype 1 (HCV-1) patients can be safely treated with dual therapy of Peg-IFN/ribavirin, and may be spared from cost and inconvenience of regimens considering the addition of HCV protease inhibitors. 23187978

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE A cohort of 269 consecutive treatment-naive HCV-infected patients with genotype 1 or 2/3 (157 Caucasians and 112 Asians) treated with PEG-IFN+RBV from January 2001 to November 2007 at four community-based gastroenterology clinics in Northern California were studied. 19904247

2010